Pfizer-Ligand's menopause-symptom drug Duavee wins FDA nod

10/4/2013 | Reuters

Pfizer and Ligand Pharmaceuticals obtained the FDA's approval to market Duavee, a combination of bazedoxifene and conjugated estrogens, for treatment of moderate to severe menopause symptoms and for prevention of post-menopausal osteoporosis. Because of health risks associated with estrogens, the drug will carry a boxed warning.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA